Navigation Links
Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
Date:9/24/2009

as led by a more than 30% increase in sales of its dairy antibiotic diagnostics. Neogen's product line to detect dairy antibiotics was recently bolstered by the launch of BetaStar((R)) Combo, which is the fastest diagnostic available for detecting beta-lactam and tetracycline antibiotic residues in milk. Tetracyclines are more widely used for treatment of bovine mastitis in the European Union than elsewhere.

Sales of Neogen's innovative rapid tests for food allergens continued their strong advance, improving approximately 25% in the current quarter compared to the prior year's first quarter. This performance was the result of significant increases in sales of diagnostic tests to detect milk, egg, almond, and gluten residues. Food processors continue to expand routine testing procedures to help prevent inadvertent contamination from reaching food allergic consumers.

Sales of the company's tests for natural toxins increased by 10% in the quarter compared to the prior year's first quarter, led by increases in sales of test kits to detect deoxynivalenol (DON) and histamine. The DON test sales increase came largely as the result of reports of high levels of the mold toxin DON in harvested grain in isolated pockets of the United States, and continuing market acceptance of the company's new test system. Histamine is a toxin produced in certain types of harvested fish, especially tuna, if they are improperly stored and transported.

Quarterly sales growth for the company's Animal Safety Division was led by an approximately 30% increase in the current quarter compared to the prior year's first quarter in products sold to veterinarians through ethical market channels. This exceptional growth included a 60% increase in sales of the company's two veterinary biologics: BotVax((R)) B, an equine botulism vaccine, and EqStim((R)), an immune system stimulant. The quarter-over-quarter increase also included an approximately 6
'/>"/>

SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Neogen Acquires Kane Enterprises
2. Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues
3. Neogen Acquires Assets of Rivard Instruments
4. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
5. Neogen Launches Quickest Test Available for Tetracyclines in Milk
6. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
7. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
8. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
9. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
10. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
11. Neogen Forms Mexican Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Repligen Corporation (Nasdaq: RGEN ) today announced ... funding to support the ongoing development of new ... Association (MDA). This grant will support the ... manufacture of a drug candidate for human clinical ... provides important funding for Repligen,s research but it ...
(Date:12/15/2009)... Constant diameter NeedleProbes™ for Atomic Force Microscopy (AFM) have ... research for studies at the liquid/air interface. The NeedleProbes’ ... meniscus height, evaporation rate and viscosity - all in a ... ... (PRWEB) December 15, 2009 -- New, constant diameter NeedleProbes ...
(Date:12/15/2009)... Dec. 15 Thomson ... ® has become the first drug pipeline database ... outcome information. This highly anticipated new content is ... month. ,, Thomson Pharma ... registries, publications, press releases, conferences, and other sources ...
(Date:12/14/2009)... Dyadic International, Inc. (Pink Sheets: DYAI) ... collaboration with The Scripps Research Institute ("Scripps") by ... the genome of Dyadic,s patented and proprietary C1 ... of the successful relationship between the two organizations ... Scripps to annotate the C1 genome for the ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5
... of Healthcare Brings 22 Years of Strategic Experience ... Prolifiq Software, Inc., today announced that Maureen A. ... of healthcare. In this role, Shaffer will lead ... for sales representatives in the increasingly complex regulatory ...
... Statistically Significant Improvement in Overall Survival -- First Active ... to be Presented at Plenary Session at Upcoming AUA ... Today at 9:00 AM ET -SEATTLE, April 14 ... that the pivotal Phase 3 IMPACT study of PROVENGE(R) ...
... 14 BioVex Inc, a company developing next ... infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial ... treated patients with Stage III and Stage IV melanoma had ... with sites in the United Kingdom, Germany and Australia due ...
Other Biology Technology:Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 2Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 3PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 2PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 3PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 4BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4
(Date:12/15/2009)... can look forward to ultra-low powered or self ... mobile phones. This is made possible with power ... critical elements for power optimisation and higher energy ... IC design is the key enabling capability for ... nation in advanced analog and mixed signal design ...
(Date:12/14/2009)... -- Researchers at Rice University and Baylor College of ... be tracked in real time with MRI as it ... fluorescent dye and kills them with heat. The all-in-one ... growing field called "theranostics" that develops technologies physicians can ... procedure. , The research is available online in the ...
(Date:12/14/2009)... study to date of the proteins in a species ... clues to how similar regeneration could be induced in ... at Indiana University-Purdue University Indianapolis and colleagues investigated over ... a type of salamander that has the unique natural ... with the hope that this knowledge will contribute to ...
Breaking Biology News(10 mins):NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Tracking new cancer-killing particles with MRI 2IUPUI researchers tackle protein mechanisms behind limb regeneration 2NIST Tests Identify IriTech as Iris Recognition Leader 10240 1NIST Tests Identify IriTech as Iris Recognition Leader 10240 2NIST Tests Identify IriTech as Iris Recognition Leader 10240 3Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 1Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 2Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 3Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 4NEDD9 protein supports growth of aggressive breast cancer 58760 1NEDD9 protein supports growth of aggressive breast cancer 58760 2
... Italy and Virginia Tech in the United States have ... for the production xanthurenic acid (XA) in Anopheles gambiae, ... in the sexual reproduction of the malaria parasite (Plasmodium ... of XA could be an avenue for development of ...
... Results from a new, five-year study show that regular use ... breast cancer by up to 71 percent and may offer ... cancers. , The study findings were released today at ... in Washington, D.C. , "We believe this is the ...
... For ants it's a way of life! Scientists at the ... learn how to visually judge the height of horizontal barriers ... down. Tobias Seidl will be presenting his latest research findings ... on Tuesday 4th April. , Desert ants generally scurry around ...
Other Biology News:Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
Biology Products: